PMA Panel Asks TherOx For New Data On Cath-Lab-Based Oxygen Therapy
This article was originally published in The Gray Sheet
FDA's Circulatory System Devices advisory panel is encouraging TherOx to sponsor a new clinical trial of its SSO2 SuperSaturated Oxygen Therapy Downstream system to demonstrate the therapy improves clinical outcomes in heart attack patients
You may also be interested in...
When it comes to treating acute heart attack patients, primary percutaneous coronary intervention (PPCI) remains the gold standard of care. And while this life-saving procedure restores blood flow through the coronary artery, perfusion in all areas of the heart may not occur. In this article, we'll highlight three innovative medtech companies that have developed very different solutions to try to improve upon the current standard of care and hear perspectives from interventional cardiologists.
Research news on hip replacements, a spinal cord stimulator and more.
The complex calculations of Bayesian statistics are not likely to become standard for FDA device submissions anytime soon, but they could help streamline clinical trials in many more instances, CDRH's top statistics official says